PLx Pharma (PLXP) Climbs 9.00% on August 5

Equities Staff  |

Shares of PLx Pharma Inc. (NASDAQ: PLXP) rose 9.00% Friday.

As of 12:00:00 est, PLx Pharma is currently sitting at $2.24 and has moved $0.185 per share in trading so far.

PLx Pharma has moved 3.59% over the last 30 days and has a YTD change of 73.16% based on the previous close.

The company expects its next earnings on 2022-08-12.

For technical charts, analysis, and more on PLx Pharma visit the company profile.

About PLx Pharma Inc.

PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.

To get more information on PLx Pharma Inc. and to follow the company's latest updates, you can visit the company's profile page here: PLx Pharma Inc.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content